Growth Equity Investment from Seacoast Capital

Healthcare
Growth Equity Investment from Seacoast Capital

Summary

Baird served as the exclusive financial advisor to SkinCure Oncology, LLC on this transaction

About

SkinCure Oncology, LLC (“SkinCure” or the “Company”) recently received a growth equity investment from Seacoast Capital (“Seacoast”). Terms of the transaction were not disclosed.

SkinCure is a leading provider of turnkey image-guided superficial radiation therapy (IG-SRT) for dermatologists. IG-SRT is a non-invasive treatment for non-melanoma skin cancer that provides similar cure rates to traditional surgery while avoiding cutting, scarring, or pain. The Company purchases and installs the IG-SRT machine, performs the procedures, and completes all the billing and collections, offering numerous benefits to dermatologists. SkinCure operates 96 sites across 23 states and is headquartered in Burr Ridge, Illinois.

Founded in 1994, with offices in Boston, Massachusetts and San Francisco, California, Seacoast Capital invests non-controlling growth capital in partnership with management in lower middle market companies. Seacoast is industry agnostic and typically invests $5 million to $25 million of capital in companies with $10 million or more in revenue and $2 million or more of EBITDA. Capital is used to support growth, refinancings, acquisitions, family ownership and wealth transfers, shareholder liquidity events, or management buyouts. Now managing its fourth fund, Seacoast Capital Partners IV, L.P., Seacoast continues to actively seek new investment opportunities.
CONTACT US TO LEARN MORE
Healthcare
Growth Equity Investment from Seacoast Capital
Date
July 2019
Company
SkinCure Oncology, LLC
Transaction
M&A
Sectors
Healthcare
Target Location
North America
Acquiror Location
North America

Share